In 2021, Arthanari group developed a new type of eIF4E inhibitor i4EG-BiP based on the crystal structure and proved that the inhibitor could inhibit the proliferation of cancer cells.61 Then they designed and synthesized a series of eIF4E degraders based on the binding mode of i4EG-BiP and eIF4E.62 Through the degradation activity test, it was found that the degrader 32 (d4E-4, Fig. 8) and the degrader 33 (d4E-6, Fig. 8) showed certain eIF4E degradation activity. The gene discussed is EIF4E; the disease is cancer.